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abstract
The EORTC Pharmacology and Molecular Mechanism Group (PAMM) focuses on
applied research to translate basic/fundamental research discoveries in cancer
biology into new drug discovery and development. PAMM provides a unique
platform on the pharmacology, pharmacokinetics, pharmacodynamics of drug
effects, molecular mechanisms of anticancer agents, and drug-related molecular
pathology. For these purposes the group stimulates the interaction between
basic scientists and clinicians in order to perform translational research on the
pharmacology and molecular mechanisms of anticancer agents in Europe. The group
has extensive expertise in various disciplines of pharmacology and has developed
standards for studies performed in conjunction with clinical trials equivalent to
those of good laboratory practice (GLP). The group serves as master organization
for other EORTC (sub-)committees in the maximal interest of these groups and
of the EORTC as a whole. PAMM merged with Preclinical Therapeutics Models
Group (PTMG) in 2000 and with the Screening and Pharmacology Group (SPG) in
2003. The latter group continued as the Drug Discovery Committee within PAMM.
The groups have always been involved in the development of anticancer agents,
evolving from platinum analogs, anthracyclines, nitrosoureas, antifolates in the
1980’s, to drugs derived from natural sources (trabectedin, taxanes) in the 1990’s,
and anti-signaling drugs, DNA alkylators, in the last decade. Several of these drugs
have been registered. Mechanistic studies focused on drug activation/inactivation,
target (DNA, receptors) in relation to efﬁcacy and toxicity such as with several
antimetabolites (5-ﬂuorouracil, methotrexate), topoisomerase inhibitors (irinotecan),
tyrosine kinase inhibitors (imatinib), acridones (C-1311), etc. The group recently
included pharmacogenetics in the identiﬁcation of genetic polymorphisms in order
to use this information for personalized therapy.
© 2012 European Organisation for Research and Treatment of Cancer.
1. Introduction
The EORTC Pharmacology and Molecular Mechanism
Group (PAMM) was established as the EORTC Pharma-
cokinetics and Metabolism (PAM) project group in early
1978 and had its ﬁrst formal meeting in December 1978
in Cambridge, UK. The meeting was initiated by a
small group of oncologists and pharmacologists who
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Table 1 – List of EORTC PAMM, SPG and PTMG ofﬁcers
Year EORTC PAM
Chair Secretary
EORTC SPG
Chair
EORTC CASG
Chair
NCI cpds
Chair
1972 L.M. van Putten, Rijswijk
1978 J.F. Smyth, Edinburgh H.M. Pinedo, Amsterdam F. Spreaﬁco, Milan
1979 W.J.F. van der Vijgh, Amsterdam
1982 K. Harrap, Sutton J.G. McVie, Amsterdam B.W. Fox, Manchester M. Aapro, Genolier
1985 J.G McVie, Amsterdam P. Workman, Cambridge
1987 M.G.M. Stevens, Birmingham
1988 P. Workman, Cambridge M. D’Incalci, Milan
1990 J.A. Double, Bradford
1991 M. D’Incalci, Milan D.R. Newell, Newcastle
1994 D.R. Newell, Newcastle J.H. Schornagel, Amsterdam C. Dittrich, Vienna
1995 D.R. Newell, Newcastle
1997 J.H. Schornagel, Amsterdam A. Gescher, Leicester
2000 A. Gescher, Leicester J.H.M. Schellens, Amsterdam I. Fichtner, Berlin J.L. Merlin, Nancy J. Double, Bradford
2003 J.H.M. Schellens, Amsterdam N. Zaffaroni, Milan M. Bibby, Bradford I. Fichtner, Berlin
2006 N. Zaffaroni, Milan F. Gieseler, Kiel A.M. Burger, Detroit A.M. Burger, Detroit
2008 G.J. Peters, Amsterdam
2009 G.J. Peters, Amsterdam E. Chatelut, Toulouse
2011 A. Westwell, Cardiff
cpds, compounds.
Treasurers of the PAMM: A. Gouyette (1987–1991); J. Robert (1991–2003); A. Larsen (2003−). J.G. McVie served as EORTC president (1994–1997);
the late Tom Connors (1991–1997), M. D’Incalci (1997–2000) and D.R. (Herbie) Newell (2000–2003) served as chair of the Laboratory Division;
P. Workman (1991–1993) and M. D’Incalci (1994–1997) as chair of the New Drug Development Committee; J. Double as treasurer of the EORTC.
Others served (or still serve) as member of the TRAC, NDAC or on the board of the EORTC. Several members subsequently served as ofﬁcer of
other groups.
felt that there was a lack of interaction in the ﬁeld of
drug development. When the group was established, it
formulated three main functions: (1) to provide a forum
for investigators working on the clinical pharmacology
of anticancer drugs, (2) to explore the potential for
cooperation between different European centers working
on the pharmacology and metabolism of anticancer
drugs, and (3) to provide a link between the EORTC
Screening and Pharmacology Group (SPG) and the Early
Clinical Trials Group (ECTG). Dr. John Smyth (then at
the Institute of Cancer Research [ICR] in Sutton, Surrey)
was the ﬁrst Chair. The ﬁrst two aims still form the
basis for the current PAMM, and regarding the third aim,
the EORTC SPG has been part of PAMM as a separate
committee, the Drug Discovery Committee (DDC) since
2003. Interaction with the ECTG (since 1995 the ECSG,
the Early Clinical Trials Study Group and since 2002
the New Drug Development Group) has now been
replaced by interactions with several of the disease-
oriented groups with a focus on translational research.
The SPG was established in 1972 with the aim to
provide facilities for drug screening and its further
development. The former Clonogenic Assay Screening
Group (CASG) was established in 1981 as a subgroup of
the ECTG and initially named the Clonogenic Assay Study
Club (CASC), and was renamed in 1993 as the Preclinical
Therapeutic Models Group (PTMG). It merged with
PAMM in 2000. These mergers were natural processes
since the groups usually met at the same time and
many activities became joint activities (Table 1, Fig. 1).
Naturally the three groups had many achievements in
drug development; within the framework of the groups
several new chemical entities (NCEs) were developed,
while the groups also provided early screening for
antitumor activity of NCEs associated with proper
preclinical pharmacology and mechanism of action
studies, followed by clinical pharmacology studies in
close collaboration with pharmaceutical companies and
The PAMM group connections
PAMM
1991–
PTMG 2000
CASG 1981–1991
PAM 1978–1991SPG 1972–2003
DDC
2003
Fig. 1 – PAMM Connections. The short connection (2006–
2009) of the imaging group is not shown since this group
was re-established as the Imaging Group in 2009.
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Table 2 – Special meetings of the EORTC-PAMM and SPG alone or with other organizations
1. First PAM meeting on “Drug interactions in cancer Chemotherapy”, December 5−7, 1978, Cambridge, UK
2. Joint BACR, PAM and SPG meeting, March 24−27, 1985, Aston University, Birmingham
3. New concepts in anticancer drug design (SPG), December 10−11, 1986, Rijswijk, The Netherlands.
4. 10th Anniversary meeting of the PAM group; special PAM-SPG: symposium: Chloroethyl nitrosoureas: the beginning of the end or the
end of the beginning? December 14−17, 1988, Jesus College, Cambridge, England
5. Special BACR-PAM symposium: The cell membrane and cell signals as targets for novel anticancer drugs. September 14−16, 1989,
Queen’s College, Cambridge, England
6. Screening for bioreductive anti-cancer agents (PAM-SPG). July 6−7, 1989, Bradford, England
7. Target-speciﬁc agents: antisense oligonucleotides, new DNA cleaving molecules and immunomodulatory molecules (SPG). December
7−8, 1989, Toulouse, France
8. Contribution to the International Symposium on Immunodeﬁcient mice in oncology (SPG). November 7−9, 1990, Freiburg, Germany
9. Novel approaches in cancer therapy, (PAMM, SPG and AWO/Phase I/II study groups). December 1−4, 1993, German Cancer Research
Center, Heidelberg, Germany
10. Acridine derivatives as potential antitumor agents (SPG). June 17, 1994, Manchester, England
11. Standard Operating Procedures (SPG). January 21,1998, Nancy, France
12. 20th Anniversary Meeting of PAMM, PAMMsterdam, January 20−23, 1999, Amsterdam, The Netherlands
13. Special PAMM, SPG symposium on In Vivo models, January 31 − February 3, 2001, Verona, Italy.
14. First PAMM Functional Imaging Joint symposium, January 26−29, 2005, Arcachon, France
15. 30th Anniversary Meeting; a special EGAM-PAMM symposium. March 17−18, 2009, Brussels, Belgium
the ECTG. 1 Many of these NCEs are now registered as
an anticancer drug and form an important and essential
constituent of treatment regimens for many cancer
types. Several of these achievements are discussed in the
following sections.
Ofﬁcers of the three groups, the PAM, SPG and CASG,
always contributed intensively to the EORTC, both as a
scientiﬁc contribution to early preclinical and clinical
drug development, and by supporting the EORTC. Several
chairs and ofﬁcers of the groups have served on the
EORTC Board either as member, but also as EORTC
president, treasurer, or otherwise such as head of the
Laboratory Division (Table 1). Members of the groups
also initiated many international activities; several PAM
and PAMMmeetings were jointly organized with national
organizations as well as with other European and
American groups. Recently collaborations with other
continents were established as well (Table 2). Hence
the three groups served (and the current PAMM as
well) as an excellent basis for many collaborations
advancing science, cancer research and promoting the
careers of many young scientists. PAMM meetings are
characterized by open discussion and care is taken that
young scientists get the chance to present their data
for a critical but friendly audience. Hence, each meeting
is concluded by giving an award to the best young
investigator presentation.
2. The EORTC Screening and Pharmacology
Group (SPG)
The SPG is one of the oldest EORTC groups (Table 1).
It was established in 1972 out of a merger between
the Experimental Screening Group and the Preclinical
Pharmacology Group. In 2003 the group merged with
PAMM, and its work was continued as the DDC. The
main objective of the SPG was to provide antitumor
and toxicity testing systems to investigate new agents
and study their mode of action, toxicity, and other
pharmacological properties. In this way the group may
alert scientists (within the EORTC) to NCEs that are
potentially interesting in the treatment of cancer. For this
purpose drug dossiers were made available. The SPG and
now the DDC has members in the major cancer research
institutes of Europe. The membership is a balance of
chemists, biologists, and clinicians with an interest in
many aspects of new drug development such as syn-
thesis, primary screening, secondary evaluation, mode of
action, toxicology, etc. This close collaboration between
various disciplines facilitates structure/activity studies
and analog development to ensure that only agents with
a real potential will progress to clinical trials.
All meetings of the SPG and now the DDC are held
under a conﬁdentiality agreement, and all members
sign a statement declaring that results of the examined
compounds will not be discussed or disclosed outside
the membership of the group. The business meetings are
typically round-table discussions on chemistry, screening
results, pharmacology, and toxicology for a range of
different compounds. The aims of the meetings are
to collate information from the various laboratories,
identify areas where further work is needed, and
produce dossiers on new drugs for submission to the
New Treatment Committee for possible progression to
clinical trials. The nature of the drug dossiers has
changed with time and included 1,2:5,6 diepoxyhexane
(1982), disuccinyl-dianhydrogalactitol (DiSu-DAG) (1983),
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Table 3 – List of miniprojects supported by the EORTC-SPG and DDC group
1985
1. Synthesis of potential bioalkylating cyclopentane dimethane sulfonates (Reinhoudt).
2. Synthesis of 2-chloroethyl-N-nitrosocarbamoyl (CNC) amino acids and -dipeptides and their methylamides for testing in experimental
tumor models (Eisenbrand, Atassi).
3. Comparison of tumor growth inhibitory and toxic effects of BCNU, 5-FU, a combination of BCNU + 5-FU and that of B-3839 (Somfai).
1986
1. Antitumor activity of B compounds against subcutaneous colon 38 carcinoma (Atassi).
2. Activity of N-[N1-(2-chloroethyl)-N1-nitrosocarbamoyl (CNC)]-alanine and derivatives against a panel of transplantable
adenocarcinomata of the mouse colon (Double).
1987
1. Synthesis of B.3839 (Reinhoudt).
2. Effects of routes of administration of TCNU on its plasma, tissue and tumor concentrations (Double).
3. The inﬂuence of routes of administration of TCNU on antitumor activity in a panel of MAC tumors (Double).
1988
1. In vitro and in vivo antitumor activity of mitomycin C and three mitosene analogues (Verboom, Lelieveld, Fiebig, Double).
1989
1. Synthesis and testing of E2-linked WV14 (Reinhoudt, Eisenbrand).
2. Synthesis and testing of hormone-linked mitosene derivatives (Reinhoudt, Eisenbrandt).
3. Determination of the antitumor activity and bioreductive potential of the mitosene GBJ584 (Double, Lelieveld).
4. Pharmacokinetics of “B compounds”; correlation with anti-tumor activity (Double, McElhinney).
1991
1. In vitro/in vivo antitumor activity of a series of indolo-(2,3-b)quinoxalines (Cros, Double, Lelieveld).
2. Synthesis and testing of some 2-arylbenzothiazoles (Stevens, Double, Lelieveld).
3. Synthesis of seven nitrosoureas with pyrimidin-3-yl substituents for comparison with effective N1 analogues and for DNA cross-linking
studies (McElhinney, Double).
4. Novel heterocycles as potential protein tyrosine kinase inhibitors (McElhinney, Stevens, Lelieveld).
2002
1. Synthesis and biological investigations of alkylating agent-RGD peptide conjugates (Su¨li-Vargha, Giavazzi).
2003
1. NQO1-Targeted prodrugs for cancer therapy: In silico screening of virtual libraries and identiﬁcation of novel agents (Jaffar, Bibby,
Stratford).
2. Preparation, characterization and in vivo testing for antitumor activity of a candidate pyrrolo-tetrazinone (Cirrincione, Fichtner).
2005
1. In vitro and in vivo activity and mechanism of action of multi and duplex drugs (Fichtner, Schwendener, Schott, Peters).
2006
1. Synthesis and evaluation of selective inhibitors of the E3 ubiquitin ligase BCA2 for potential treatment of invasive breast cancer
(Westwell, Burger).
2009
1. Synthesis and biological evaluation of inhibitors of human lactate dehydrogenase 5 as cancer starvation agents (Minutolo, Peters).
molecular combinations of 5-FU and BCNU (B.3839)
(1986), 2 CNC-L-alanine-dihydrotestosteron-17-ester (E91)
(1987), amino acid carriers of chloroethyl-nitrosoureas
(E10, 79, 94, 126, 127) (1987), molecular combinations
of 5-FU and nitrosoureas (B.3995 and B.3996) (1988),
and imidazoacridinone C-1311 (1997). Research on these
drugs was often supported by mini projects which
were funded out of the group’s income (until 2000 the
annual contribution of the EORTC with occasionally
grants from the NCI), and intended to support drug
development with feeder money (Table 3). Several
compounds developed within the framework of the
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SPG and often in collaboration with PAMM went
into clinical development: Flavone acetic acid, 3 EO9
(Oostveen, Pinedo), AQ4N (Laurence Patterson), temo-
zolomide (Stevens), imidazoacridinone C-1311 (Konopa),
nucleoside prodrugs, Patrin2, Phortress 4 (Stevens, Brad-
shaw, Westwell); 2-(4-amino-3-methylphenyl)-5-ﬂuoro-
benzothiazole L-lysylamide dihydrochloride. 5 Several of
these drugs will be discussed in more detail in the
following.
2.1. Development of temozolomide
Temozolomide was synthesized as a DNA interacting
agent by Prof. Malcolm Stevens (then at Aston University,
Birmingham; from 1992 at the University of Nottingham,
and SPG Chair from 1987 to 1990) and initially tested
within the facilities of the SPG. Although in vitro
activity was minor, it was the belief of the group
that this would not be important because it was
designed to be activated in vivo. 6 These studies also
led to the ﬁnding that temozolomide could pass the
blood–brain barrier efﬁciently and proved to be active
against animal brain tumor models. Pivotal studies by
the late Ed Newlands showed a good activity against
glioblastoma. 7,8 Randomized studies from the EORTC
Brain Tumor Group clearly showed an advantage of
temozolomide combined with radiation compared with
radiation alone and formed the basis for its registration. 9
This study also demonstrated the important role of
methylation of the MGMT gene promoter. 10
2.2. Prodrugs, mutidrugs and drug carriers
Many drugs in development are administered in a
suboptimal way: they are either insoluble, have a
short half-life, have a poor uptake, or are extensively
catabolized to toxic breakdown products. Even many
commonly used, successful drugs are not always given
in an optimal way. Therefore several SPG members, often
in collaboration with other SPG or PAMM members or
a pharmaceutical company, investigated several ways
to optimize administration. When drugs are combined,
either as two active drugs, modulating agents, or co-
medication, these effects are either diminished or even
increased. In order to improve delivery or bypass un-
wanted side-effects several attempts have been pursued.
Drug delivery has been improved by administration of
the drugs in liposomes, nanoparticles, antibody-directed
enzyme prodrug therapy (ADEPT), or more recently by
gene-directed enzyme prodrug therapy (GDEPT).
With ADEPT an enzyme is coupled to an antibody
which ideally will speciﬁcally recognize a tumor cell.
This is delivered together with an inactive prodrug,
systemically, which is speciﬁcally activated by this
enzyme at the tumor site to become a toxic drug.
With GDEPT a gene is delivered with the information to
produce this enzyme in the tumor, so that the inactive
prodrug can be converted into the toxic drug. Several
investigators within the SPG and PAMM worked on
this concept with nitroreductase as the best described
example. Nitroreductase from E. coli can activate the
prodrug CB1954 to a bifunctional DNA cross-linking drug
enzyme, a concept which was developed at the ICR. 11,12
Other prodrugs were developed to improve delivery
and uptake by cancer cells, since a frequently observed
resistance mechanism for nucleoside analogs is de-
creased uptake. Hence prodrugs of cytarabine and gem-
citabine were developed by attachment of a fatty acid
tail (elaidic acid) to the sugar moiety; the ara-C-prodrug
elacytarabine had impressive activity against solid tumor
xenografts, while ara-C does not. 13 The gemcitabine
prodrug CP-4126 (now developed as CO1.01) had a similar
proﬁle as gemcitabine but could also be given orally. 14
Both drugs bypassed resistance due to nucleoside
transport deﬁciency, were developed in collaboration
between the EORTC New Drug Development Ofﬁce and
several SPG laboratories, and are in Phase II and III
clinical trials. Other approaches included multidrugs,
two drugs linked by a lipid which would enhance drug
delivery, with the advantage of delivering two cytotoxic
drugs to the tumor simultaneously. Nanoparticles have
also been investigated by the SPG and the DDC.
2.3. The NCI compounds initiative
In 1993 an important collaboration was established
between the SPG and PAMM with the NCI and CRC
(Cancer Research Campaign, now Cancer Research UK),
the so-called NCI compounds initiative. These joint
forces aimed to speed up the development process of
NCEs in Europe with emphasis on compounds synthe-
sized in Europe, especially compounds synthesized by
groups unfamiliar with the drug development process.
The intention of this initiative was to join forces
on the various aspects of drug development: initial
activity screening, formulation, mechanism of action,
toxicology, and preclinical pharmacokinetics, with an
emphasis on novel drug entities. The procedure involved
an initial screen of compounds tested by the NCI in
the 60-cell line panel, the hollow-ﬁber assay and/or
xenografts. Based on the novelty of the structural
formula, the selective activity in the 60-cell lines panel,
the uniqueness in the COMPARE analysis, the in vivo
activity and the chemical properties, a decision was
made whether the NCE was worthwhile to develop
and by whom. Because of the insolubility of many
compounds, formulation became amajor effort to ensure
reliable administration. 15 This also required a different
approach for drug analysis, but due to the expertise of the
many collaborating centers, this was usually solved, and
this expertise also enabled evaluation of many classes of
drugs including drugs targeted against cytotoxic targets
such as novel nitrogen mustards, antimetabolites, DNA
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intercalators, tubulin-directed drugs, and more recently,
non-toxic drugs targeting signal transduction, tumor
physiology, and angiogenesis. This effort led to many
fruitful collaborations often facilitated by the laboratories
themselves. Furthermore, accumulating insight in drug
development of speciﬁc classes led to omission of
certain groups, such as tubulin-directed drugs. The
NCI always actively participated in this joint effort
by attending the NCI compounds meeting, providing
the drug information, the initial drug screening, active
discussions and ﬁnancial support. The CRC provided
support for drug screening.
3. The EORTC Clonogenic Assay Study Group
(CASG)
The CASG was formed in 1981 as the CASC in order
to coordinate European activities on the use of the
clonogenic assay as a tool to select which drug would be
the most suitable for a certain patient. This research was
initiated following the seminal publication of Salmon-
Hamburger 16 on the use of the clonogenic assay to select
drugs for individual patients. Both in the United States
and in Europe this idea was received enthusiastically,
because it represented one of the ﬁrst attempts to
allow personalized treatment. The rationale behind this
principle was novel at that time and similar to current
stem cell theories. It was reasoned that not all tumor
cells would contribute to the development of a tumor,
but that only a few “very malignant” cells would lead
to tumor cell formation. In the current terminology
these cells would be called cancer stem cells. Hence,
selecting the drug which would kill this speciﬁc cell
would most likely be the most active drug against the
tumor from the patients. Therefore, many laboratories
collected primary tumors from patients during surgery,
isolated tumor cells and plated these cells on agar in
order to form colonies. The plating efﬁciency of the
clonogenic assay was usually less than 1 out of 10,000
or 100,000 or even less, similar to the low abundance of
stem cells. A number of laboratories were very successful,
leading to spin-off companies who still use a modernized
form of the clonogenic assay to test for drug activity.
However, despite the simplicity of the idea, execution of
the clonogenic assay encountered many problems. The
CASG took this challenge and established a European
forum in order to validate the clonogenic assay across
European laboratories for a number of cell lines
but always in comparison with the colon carcinoma
cell line WiDr. This type of validation was a hallmark
of the group. 17,18 The clonogenic assay was routinely
performed on agar or methyl cellulose, while the used
media consisted of many unknown additions, such as
bacterial extracts, various types of serum, growth factors
extracted from tumor ﬂuids, such as ascites or pleural
effusions. Although this type of research did not yield
reproducible data when compared between laboratories,
within several laboratories in which the methodology
was validated very impressive correlations between the
inhibition of colony formation and therapeutic efﬁcacy
were found. Furthermore, characterization of the various
unknown proteins considered to be essential for colony
formation led to the identiﬁcation of many currently
well-known growth factors, such as Vascular Endothelial
Growth Factor, Insulin Growth Factor, Platelet-Derived
Growth Factor, Epidermal Growth Factor and others. 19
Because of the above-mentioned challenges, the CASG
decided to extend its focus and changed its name. In 1991
it was called In vitro Study Group, but in 1993 it changed
its name to the PTMG to use other model systems
as well, such as two-dimensional monolayer cultures
and suspension cell lines in comparison with other
three-dimensional culture systems such as spheroids, or
multilayer cultures, and other types of assays such as
the SRB, MTT and ATP assay. 20,21 The easy availability
of different cell lines in the participating laboratories
enabled studies in many cell lines, similar to the NCI
60-cell line panel with the WiDr cell line as the golden
standard. Screening efforts were naturally accompanied
by mechanistic studies, completely in line with the aims
of PAMM, leading to the merging with PAMM. Hence, the
last joint PTMG paper was a PAMM paper as well. 22
4. The EORTC Pharmacokinetics and Metabolism
Group (PAM)
The ﬁrst meetings of PAM focused on development of
suitable assays for the many new drugs which were
introduced in the 1970’s and 1980’s. The relatively new
technique of HPLC offered an opportunity for reliable,
sensitive, and reproducible drug measurements and
performance of pharmacokinetic studies in phase I and II
studies. Also other techniques were introduced, such as
Radio-Immuno-Assays, and Flameless Atomic Absorp-
tion Spectroscopy which was essential to understand
the pharmacology and molecular mechanisms of not
only cisplatin but also its novel analogs such carboplatin
and oxaliplatin, and to understand why other analogs
such TNO-6 were too toxic. It is not surprising that
several early PAM members (H.M. Pinedo, J.F. Smyth)
were intensively involved in the ECTG, and many ECTG
members remained PAM (later PAMM) members. This
interaction between clinicians and scientists was unique
in the 1980’s and formed a ﬁrm basis for inclusion of
translational research in these clinical studies. These
studies were often a spin-off of mechanistic studies to-
wards the metabolism of these novel anticancer drugs.
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4.1. Pharmacokinetics-guided dose escalation and drug
administration
Development of anticancer drugs from animals to
patients is a tedious process, in which the limiting factor
for any drug is its tolerability in patients. Therefore the
escalation steps, usually following a modiﬁed Fibonacci
scheme, are very conservative with careful monitoring
of all patients (see a monograph on these aspects
with many PAM/PAMM contributions 23). This means that
many patients are initially being dosed at very low levels,
and that it takes many steps to reach the maximum
tolerated dose (MTD). Therefore the PAM initially drafted
a number of guidelines in order to streamline the drug
dose escalation within EORTC phase I trials. Using mouse
models, an algorithm was developed which based the
ﬁrst dosing step on the MTD in mice (ﬁrst dose 1/10 of
the LD10 in mice), while the initial dose escalation was
based on the mouse pharmacokinetics (PK), naturally ac-
companied by careful monitoring of human PK. 24,25 This
required a stringent quality assurance of assays, always a
major aspect of PAMM activities. The initial studies faced
a number of challenges, 26 but various drugs were entered
into the clinic and were developed according to this
algorithm which still forms the basis for drug escalation
in Phase I studies, albeit with several modiﬁcations.
Examples of these drugs include several alkylating
agents, anthracyclines, platinum analogs and anti-
metabolites, 27 although it was assumed that the concept
would be less accurate for antimetabolites. However,
despite a short plasma half-life, antimetabolites often
have a much longer tissue half-life due to extensive
metabolism leading to trapping in the tissues.
4.2. Development of novel platinum analogs
The excitement following the introduction of cisplatin
in the 1970’s which led to cure of several previously
incurable diseases (e.g. testicular cancer) was dampened
by the serious side effects. Hence efforts of several
PAM and SPG laboratories were directed to develop
novel platinum analogs in close collaboration with
Johnson Matthey and several pharmaceutical companies,
such as Bristol-Myers, while several SPG chemists were
involved as well. 28 This led to the development of
a series of “JM-platinums” and other series, such as
the TNO compounds. 29 The ICR played a seminal role
combining chemistry, testing in model systems, and
clinical studies. This was the start of the career of
the late Lloyd Kelland, who was responsible for testing
many of these analogs. 30 There was a fruitful cross-
fertilization leading to several other series of compounds
such as the TNO series but also other types of platinum
complexes. Unfortunately, many of these compounds
were either inactive or were associated with too many
side effects such as TNO-6, co-developed by TNO in
Rijswijk and the VU University Medical Center in
Amsterdam. A successful example of these joint efforts is
carboplatin, while satraplatin (JM-216) is still a potential
candidate for oral application of a platinum analog.
4.3. Personalized treatment with carboplatin
In contrast to cisplatin, which carries a major risk
of nephrotoxicity, the development of carboplatin was
hampered by the development of myelotoxicity. However,
already at an early stage it was recognized that
this toxicity was exposure dependent. The increasing
insight in the association of PK−PD relationships was
used to deﬁne the association between carboplatin
pharmacokinetics, clearance, and thrombocytopenia in
a clinical study coordinated by Hilary Calvert (then at
the Institute of Cancer research, Sutton, Surrey) together
with Herbie Newell, PAMM chair from 1994 to 1997. This
led to a simple formula, the so-called Calvert formula,
still widely used to dose carboplatin, 31 in which the
clearance is used to dose carboplatin in order to get
the target area-under-the curve (AUC) and thereby
prevent excessive toxicity and maximize the efﬁcacy.
This can be considered as one of the earlier forms of
personalized treatment. Because of the inaccuracy of the
assays for clearance, the change in methodology, and
extensive use in combinations a number of adaptations
have been made. Furthermore, the formula has been
adapted for use in various groups of patients including
young patients. 32 Population pharmacokinetic analysis
of carboplatin helped to deﬁne the differences between
these populations and was performed to optimize the
algorithm.
5. The Pharmacology and Molecular Mechanism
Group (PAMM)
The change in medicinal chemistry, analytical tech-
niques, imaging techniques, molecular biology, and
cell biology in the 1980’s and early 1990’s led to a
shift in the way drugs were developed, and most
importantly, the classes of drugs were changing as
well. The challenge of the last decade included the
question of how to evaluate novel classes of drugs
such as several anti-angiogenic drugs and tyrosine
kinase inhibitors. Hence the emphasis of the PAM
meetings changed from classical pharmacokinetics to
many additional aspects of pharmacology (including
pharmacodynamics, later pharmacogenetics, but also
cellular pharmacology and molecular pharmacology).
Therefore it was decided to change the name to
Pharmacology and Molecular Mechanisms (PAMM).
PAMM became involved in drugs targeting signaling,
reversal of multidrug resistance, novel DNA intercalators,
drugs from natural resources, drugs targeting growth
factors, prodrug activation systems, drugs targeting the
protein degradation and recycling (proteasome, heat-
shock proteins, aminopeptidase, farnesylation), 33 p53
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and other apoptosis-directed drugs, several types of
prodrugs and formulations, 34 and chemoprevention. The
intensive interaction with the SPG and PTMG members
enabled the use of many model systems to investigate
drug action and develop potential biomarkers alongside
the clinical and preclinical studies. Some examples of
these drug classes are discussed in more detail below.
5.1. Development of EO9 (EOquin, apaziquone)
Initially, EO9 was jointly developed by the University
of Amsterdam and the VU University, but it rapidly
became a joint effort of PAMM, SPG and the EORTC New
Drug Development Ofﬁce in which a number of their
laboratories became involved. 35 It was part of a series
of indoloquinone derivatives of mitomycin. Its favorable
activity in a number of preclinical in vitro and in vivo
models led to its selection for further development.
EO9 is a prodrug belonging to the class of bioreductive
agents and needs to be activated by an oxidoreductase
in order to generate cytotoxic metabolites 36; the activity
of the drug is related to the activation of DT-diaphorase
(NQO1) in normoxic tumors, but it is preferentially
activated in hypoxic tumors. 37,38 Unfortunately, the
Phase I and II studies were negative because of a
very poor pharmacokinetic proﬁle with a very short
half-life preventing the drug being taken up by tumor
tissues. 39,40 Because of the poor drug delivery proﬁle,
further development turned this into an advantage, and
the drug was tested in the treatment of superﬁcial
bladder cancer. 41 The longer local exposure of these
tumors not only permitted drug penetration, but the
hypoxic conditions were in favor of this drug as well; poor
plasma pharmacokinetics would prevent any systemic
drug accumulation and toxicity. In several Phase II
studies complete responses in up to 2/3 of the patients
were achieved. 42 Recurrences are infrequent, and the
drug is currently further developed for local treatment of
superﬁcial bladder cancer. The development of this drug
demonstrates that proper development which takes all
aspects into account can change poor PK proﬁles into an
advantage.
5.2. Development of antifolates
Antifolates are one of the oldest classes of anticancer
drugs, with methotrexate as the prototype. However, the
efﬁcacy of classical antifolates is limited by their uptake
(mediated by either the folate receptor [FR], reduced
folate carrier [RFC], and the recently characterized
proton-coupled folate transporter], efﬂux by RFC or
ABC pumps, metabolism to a polyglutamate form
by folylpolyglutamate synthetase (FPGS), and target
modiﬁcation (either dihydrofolate reductase [DHFR] or
thymidylate synthase [TS]). In order to improve the
efﬁcacy of this class of drugs, the ICR and other groups
developed a number of folate analogs, but instead of
targeting DHFR, these drugs were designed to inhibit TS
which is also the target for 5-ﬂuorouracil (5-FU). The ﬁrst
prototype, CB3717, showed excellent TS inhibition and
was a good substrate for FR and RFC, although uptake
was predominantly dependent on the RFC. 43 Unfortu-
nately, the drug showed serious nephrotoxicity, 44 but
modiﬁcation of the molecule led to the development of
Tomudex™ (raltitrexed), which is an excellent substrate
for RFC and FPGS, while the polyglutamates are very
effective TS inhibitors. Tomudex’s mechanism of action
studies were a joint PAMM effort, predominantly between
Amsterdam and Sutton, 45 while clinical studies were
performed by the ECTG 46 and later by other groups such
as the EORTC Gastrointestinal Tract Cancer and Lung
Cancer Groups. 47 This led to the registration of Tomudex
for the treatment of colon cancer. Current efforts focus
on drugs which either do not need polyglutamylation
(Plevitrexed, ZD 9331) or are dependent on the FR
(BGC945). 48 The latest compound has been shown to be
selectively active in tumors with a high FR expression
and is currently evaluated in ovarian cancer which has
high FR expression.
5.3. Imidazoacridinones
Another nice example in which all groups (SPG,
PTMG and PAMM) worked intensively together was the
development of C-1311 (Symadex™). C-1311 belongs to
the group of imidazoacridinones which were rationally
designed by the Gdansk group of Prof. Konopa on the
basis of structure–activity relationship studies on mitox-
antrone. 49 The most promising analogue, C-1311, which
contains the hydroxyl group in position 8 of the imidazo-
acridinone core, is currently in phase II clinical trial.
C-1311 is rapidly transported to tumor cells, accumulates
in the nucleus, and has shown potent activity against
experimental models of murine and human colorectal
cancer in vitro and in animal studies carried out by the
SPG. The drug, which undergoes enzymatic oxidative
activation, has been shown to intercalate into DNA
and trap topoisomerase II cleavable complexes 50 but is
extruded by the multidrug resistance protein ABCG2. 51
These mechanistic studies were performed by various
PAMM, SPG and PTMG members in which the late Ange-
lika Burger was instrumental. It was shown that C-1311
treatment resulted in cell death but failed to induce
apoptosis, but cell death was possibly induced in a pro-
cess resembling abortive mitosis or mitotic catastrophe.
5.4. Trabectedin
Trabectedin (Yondelis®, also known as ecteinascidin 743
or ET-743) is a small molecule which occurs naturally in
the Caribbean tunicate Ecteinascidia turbinate. The initial
development of trabectedin was performed using the
natural product. PharmaMar developed the chemical
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synthesis of the compound used in phase II studies. Tra-
bectedin showed striking antitumor activity in preclinical
rodent models. 52 Various PAMM participants contributed
signiﬁcantly to this development predominantly focusing
on its mechanism of action. The compound binds in
the minor groove of DNA and shows a unique mode
of action. Studies performed by laboratories taking part
in PAMM (D’Incalci, Milan; Larsen, Paris) have identiﬁed
a unique pattern of response of the drug depending
on the function of different DNA repair pathways. The
most sensitive cancer cells are those with an efﬁcient
nucleotide excision repair activity and a dysfunction of
homologous recombination. These ﬁndings have been
conﬁrmed in the clinic in sarcoma patients treated with
trabectedin in trials conducted by the EORTC Soft Tissue
and Bone Sarcoma Group. In addition, the laboratory
headed by D’Incalci, Milan, has demonstrated that
trabectedin is a modulator of transcription regulation
of some cancer-related genes. These peculiar promoter-
and gene-dependent transcription effects explain the
very high activity of trabectedin against some sarcomas
whose pathogenesis is related to the deregulation of a
speciﬁc transcription factor (e.g. myxoid liposarcoma).
In addition, the same researchers (D’Incalci, Giavazzi,
Larsen) have demonstrated that trabectedin is very
effective against ovarian cancer xenografts resistant
to other anticancer drugs, such as cisplatin, and has
additive to synergistic effects in combination with
cisplatin. 53,54 These data have provided the rationale for
phase II studies in ovarian cancer that have conﬁrmed
results obtained in the laboratory. Beinen’s laboratory in
Amsterdam has developed a highly sensitive and speciﬁc
HPLC-MS method for the determination of trabectedin in
biological ﬂuids. This method was successfully applied to
characterize the clinical pharmacokinetics of trabectedin
during the early phase of its development. 55
In 2007 the European Medicine Evaluation Agency
(EMA) approved trabectedin for the treatment of soft-
tissue sarcomas and in 2009 for the treatment of ovarian
cancer. Myelosuppression is the principal dose-limiting
side-effect of the drug, but hepatotoxicity has been
frequently observed in the clinic, as well. Several PAMM
groups (Gescher, Leicester; D’Incalci, Milan) collaborated
with PharmaMar to biochemically and pathologically
characterize this toxicity in the rat, after which it was
hypothesized that the glucocorticoid dexamethasone can
inﬂuence trabectedin hepatoxicity. 56 High-dose dexam-
ethasone administered before trabectedin dramatically
abrogated trabectedin hepatotoxity in rodents without
confounding its antitumor activity, a ﬁnding which was
translated to the clinic with the same result, 57 leading to
standard application of dexamethasone in combination
with trabectedin.
5.5. The BIOMED program
In line with the traditions of the original PAM group,
Jan Schellens initiated a joint European program which
was funded by the EU in the BIOMED 2 call. The aim of
the grant was to establish a European consortium which
would ﬁnally perform a population pharmacokinetic
program on several widely used anticancer drugs in
order to optimize the treatment with these drugs.
This program involved a number of important steps,
including the characterization and motivation of several
PAMM laboratories, several large clinical centers which
would be willing and able to recruit sufﬁcient patients
for this program, cross-validation of the laboratories,
and implementation of the data. The persistence of
the coordinator Jan Schellens and the various PAMM
collaborators (Karlsson, Uppsala; Boddy & Newell, New-
castle; Chatelut, Toulouse; Van der Vijgh & Vermorken,
Amsterdam; Bruno), led to a successful program despite
the fact that not all patients could be included in
the program, especially because of various competing
Phase I and Phase II studies. This collaborative program
demonstrated the feasibility of sampling in various
centers, cross-validation of analytical techniques, and
an association of length of paclitaxel exposure with
outcome and carboplatin AUC with toxicity. 58,59 Drug
monitoring and population pharmacokinetics are recur-
ring items at PAMM meetings. 60
5.6. Inhibitors of signaling pathways
Early on PAMM recognized the importance of novel
antisignaling drugs, in which one of the early PAM
chairs, Paul Workman (now Director of the Cancer
Therapeutics Unit and Deputy Chief Executive of The
Institute of Cancer Research) played a key role. 61,62 Joint
AACR, BACR, and PAM meetings were organized for this
purpose. 63,64 The early focus was on protein kinase C
signaling and related cyclic nucleotides and on how to
combine them with cytotoxic drugs. 65 The importance of
tyrosine kinases in activation of growth factor receptors
and angiogenesis was recognized, especially because
of the expertise in the SPG group in animal models
for angiogenesis. Subsequently several prominent PAMM
members were involved in the introduction of several
new tyrosine kinase inhibitors into the clinic including
several predecessors of sunitinib such as SU5416. The
negative data with SU5416, especially toxicity, were
invaluable for successful development of newer analogs,
such as sunitinib.
6. Multidrug resistance
PAM, SPG, PTMG and later PAMM have always been
heavily involved in resistance, including multidrug
resistance. This is not surprising since the M of PAM
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stands for metabolism and the two MMs of PAMM for
molecular mechanisms, which form the basis for any
resistance genotype and phenotype. PAMM meetings
repeatedly discussed resistance to common drugs like
the classes of antimetabolites, platinum, anthracyclines,
taxanes, imdazoacridones, and recently that of tyrosine
kinase inhibitors. The role of multidrug resistance in
these classes of drugs has been investigated intensively
in many collaborative studies of PAMM members. 66
Unfortunately, the investigations on P-glycoprotein
(PgP) reverters of drug resistance of tumors were not very
successful in the clinic, since the compounds did not
improve antitumor activity of explored drugs such as
anthracyclines. However, this insight into PgP led to a
better understanding of the mechanism of penetration
of drugs into the brain and on the role of these pumps
in drug absorption from the gut. The investigation of
PgP inhibitors in order to facilitate oral administration
of drugs which are PgP substrates, holds more promise
than the resistance-reverter studies. More recently the
role of several MRPs (ABCB1, etc.) and BCRP (ABCG2) in
resistance was widely explored, and it was concluded in
several investigations that these phenomena are more
likely to be related to clinical resistance.
7. The new area of pharmacogenetics and
pharmacogenomics
The PAM and PAMM have always been very much
involved in investigations on tumor metabolism of
anticancer drugs and the role of metabolites in the
antitumor activity and toxicity of both classical anti-
cancer drugs but also the new generation of antisignaling
drugs. PAM was one of the ﬁrst groups to establish
PK−PD relationships which were rapidly reported to
be associated with genetic defects of polymorphisms.
Well investigated examples are the role of impaired
5-FU degradation by dihydropyrimidine dehydrogenase
in sometimes lethal 5-FU toxicity; especially French 67
and Dutch 68 groups were active in this ﬁeld. More
recently this ﬁeld has been extended to the investigation
of another antimetabolite, gemcitabine. Deﬁciency of its
degradation pathway (cytidine deaminase) was found
to be associated with increased side-effects but also
with a better efﬁcacy. 69,70 A collaboration between
Italian, French, Dutch and English groups to validate the
detection is ongoing. These studies were initiated by
measurement of enzyme activities and aberrant phar-
macokinetics, but rapidly it appeared that these enzyme
deﬁciencies were associated either with the absence of
gene expression or with speciﬁc genetic polymorphisms.
Similar associations have now been described, and
several times also implemented, for other drugs and
enzymes, such as CYP450 enzymes (irinotecan), various
transporters (e.g. ABCG2), glucuronidation, esterases,
etc.
8. Conclusions and future perspectives
PAMM has a tremendous expertise in the study of
drug metabolism, pharmacokinetics and the role in
drug action. It performed translational studies from
the beginning of its existence and has contributed to
the standardization of protocols for drug testing and
screening, phase I studymethodology and early protocols
for personalized treatment. The hallmark of PAMM,
interaction between clinical researchers and laboratory
scientists, has been essential for these achievements.
Currently this interaction is increasingly considered to
be essential for successful drug development. In the near
future PAMM will continue research on drug screening
and drug development in collaboration with other
groups including NCI, CRUK, GPCO, SENDO, and CESAR.
PAMM will continue to explore how implementation of
proper pharmacokinetics can enhance drug development
(see EO9) but will also explore how novel approaches
with pharmacogenetic and pharmacogenomic proﬁling
will help to personalize treatment. Interaction with the
EORTC Pathobiology and Imaging Groups has intensiﬁed
and will be essential to achieve these goals. In the
last few years the interaction with the EORTC Disease
Oriented Groups has replaced that with the ECTG and
NDDP and several collaborative projects are now being
implemented.
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